TMC207 becomes bedaquiline, a new anti-TB drug

Future Microbiology

Volumn 8, Issue 9, 2013, Pages 1071-1080

  Palomino, Juan Carlos ^a   Martin, Anandi ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

bedaquiline; drug development; drug resistance; TB

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; BEDAQUILINE; CAPREOMYCIN; DELAMANID; ISONIAZID; KANAMYCIN; LINEZOLID; MYCOLIC ACID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; QUINOLONE; QUINOLONE DERIVATIVE; RIFAPENTINE;

AMINOTRANSFERASE BLOOD LEVEL; ANTIBACTERIAL ACTIVITY; ARTHRALGIA; ARTICLE; ATYPICAL MYCOBACTERIUM; BACTERIAL CELL; BACTERICIDAL ACTIVITY; CHEMICAL STRUCTURE; CLINICAL EVALUATION; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENERGY; ENZYME INHIBITION; HALF LIFE TIME; HUMAN; IN VITRO STUDY; INCIDENCE; LOADING DRUG DOSE; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MEMBRANE VESICLE; MOLECULAR MODEL; MULTIDRUG RESISTANT TUBERCULOSIS; MYALGIA; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM ULCERANS; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SKIN INFECTION; TREATMENT DURATION; TUBERCULOSIS; VOMITING; X RAY DIFFRACTION;

ADENOSINE TRIPHOSPHATE; ANTITUBERCULAR AGENTS; DIARYLQUINOLINES; DRUG APPROVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENERGY METABOLISM; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84884138930     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.85     Document Type: Article

References (39)

1. Almeida da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J. Antimicrob. Chemother. 66(7), 1417-1430 (2011).
2. Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 54(4), 579-581 (2012).
3. Migliori GB, Centis R, D'Ambrosio L et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin. Infect. Dis. 54(9), 1379-1380 (2012).
4. WHO. Treatment of Tuberculosis Guidelines (4th Edition). WHO, Geneva, Switzerland (2009).
5. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr. Opin. Pulm. Med. 16(3), 186-193 (2010).
6. Palomino JC, Martin A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis? J. Antimicrob. Chemother. 68(2), 275-283 (2013).
7. Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope and reality. Int. J. Tuberc. Lung Dis. 16(8), 1005-1014 (2012).
8. Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3(11), e466 (2006).
9. Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int. J. Tuberc. Lung Dis. 15(7), 949-954 (2011).
10. Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med. 366(23), 2151-2160 (2012).
11. Stover CK, Warrener P, VanDevanter DR et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405(6789), 962-966 (2000).
12. Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother. 53(8), 3402-3407 (2010).
13. Diacon AH, Dawson R, du Bois J et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob. Agents Chemother. 56(6), 3027-3231 (2012).
14. Villemagne B, Crauste C, Flipo M, Baulard AR, Déprez B, Willand N. Tuberculosis: the drug development pipeline at a glance. Eur. J. Med. Chem. 51, 1-16 (2012).
15. Cheepsattayakorn A, Cheepsattayakorn R. Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis. Recent Pat. Antiinfect. Drug Discov. 7(2), 141-156 (2012).
16. Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother. 51(11), 4202-4204 (2007).
17. Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707), 223-227 (2005).
18. Lenaerts AJ, Hoff D, Aly S et al. Location of persisting Mycobacteria in a guinea pig model of tuberculosis revealed by r207910. Antimicrob. Agents Chemother. 51(9), 3338-3345 (2007).
19. Lounis N, Guillemont J, Veziris N, Koul A, Jarlier V, Andries K. R207910 (TMC207): un nouvel antibiotique pour le traitement de la tuberculose. Med. Mal. Infect. 40(7), 383-390 (2010).
20. Gaurrand S, Desjardins S, Meyer C et al. Conformational analysis of r207910, a new drug candidate for the treatment of tuberculosis, by a combined NMR and molecular modeling approach. Chem. Biol. Drug Des. 68(2), 77-84 (2006).
21. Petit S, Coquerel G, Meyer C, Guillemont J. Absolute configuration and structural features of R207910, a novel antituberculosis agent. J. Mol. Struct. 837(1-3), 252-256 (2007).
22. Koul A, Dendouga N, Vergauwen K et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3(6), 323-324 (2007).
23. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother. 53(3), 1290-1292 (2009).
24. Petrella S, Cambau E, Chauffour A et al. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob. Agents Chemother. 50(8), 2853-2856 (2006).
25. Segala E, Sougakoff W, Nevejans-Chauffour A, Jarlier V, Petrella S. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob. Agents Chemother. 56(5), 2326-2634 (2012).
26. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother. 54(3), 1022-1028 (2010).
27. Ji B, Lefrançois S, Robert J, Chauffour A, Truffot C, Jarlier V. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob. Agents Chemother. 50(6), 1921-1926 (2006).
28. Lechartier B, Hartkoorn RC, Cole ST. In vitro combination studies of Benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56(11), 5790-5793 (2012).
29. Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob. Agents Chemother. 54(7), 2840-2846 (2010).
30. Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52(8), 2831-2835 (2008).
31. Diacon AH, Dawson R, Von Groote-Bidlingmaier FT et al. A randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob. Agents Chemother. 57(5), 2199-2203 (2013).
32. Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360(23), 2397-2405 (2009).
33. Diacon AH, Donald PR, Pym A et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother. 56(6), 3271-3276 (2012).
34. Roehr B. FDA approves rifapentine for the treatment of pulmonary tuberculosis. J. Int. Assoc. Physicians AIDS Care 4(8), 19-25 (1998).
35. Dorman SE, Goldberg S, Stout JE et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J. Infect. Dis. 206(7), 1030-1040 (2012).
36. Lounis N, Gevers T, Van Den Berg J, Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob. Agents Chemother. 52(10), 3568-3572 (2008).
37. Dooley KE, Park JG, Swindells S et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J. Acquir. Immune Defic. Syndr. 59(5), 455-462 (2012).
38. Diacon AH, Dawson R, von Groote-Bidlingmaier F et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380(9846), 986-993 (2012).
39. Shang S, Shanley CA, Caraway ML et al. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob. Agents Chemother. 55(1), 124-131 (2011).